Company Overview and News
West Wits Mining Ltd (ASX:WWI) is targeting conglomerate-hosted gold with a focus on two regions, the Witwatersrand Basin of South Africa and Pilbara region of Western Australia.
West Wits Mining Ltd (ASX:WWI) has submitted two mining permit applications to enable a substantial increase in gold production from its Witwatersrand Basin Project (WBP) in South Africa.
West Wits Mining Limited’s (ASX:WWI) executive chairman Michael Quinert has increased his shareholding in the company with an on-market purchase of about 230,000 shares.
West Wits Mining Limited’s (ASX:WWI) exploration director Andrew Tunks has nearly doubled his stake in the company with the purchase of 475,000 shares.
West Wits Mining Limited (ASX:WWI) is aiming to identify conglomerate-hosted gold targets at its Tambina project in Western Australia, to test whether small-scale mining operations can recommence.
West Wits Mining Ltd (ASX:WWI) has promoted its expert exploration consultant, Dr Andrew Tunks, to sit on the company’s board as an executive director. Dr Tunks will be in charge of the group’s exploration activities in the Witwatersrand Basin of South Africa and Pilbara region of Western Australia.
West Wits Mining Limited (ASX:WWI) is in the process of applying for two mining permits to enable a substantial increase in gold production from its Witwatersrand Basin Project (WBP) in South Africa.
West Wits Mining Limited (ASX:WWI) has completed the acquisition of three mining leases within the Tambina conglomerate hosted gold project in the Pilbara region of Western Australia.
West Wits Mining Limited (ASX:WWI) is planning to secure mining rights across the whole Witwatersrand Basin project (WBP) in South Africa to substantially scale up gold production.
West Wits Mining has announced a significant material increase at the Witwatersrand Basin, lifting its mineral resource estimate from 1.38 million ounces to 3.26 million ounces.
West Wits Mining Ltd (ASX:WWI) has a mineral resource upgrade on the table, and the ASX has granted the company a trading halt to prepare the final details.
West Wits Mining Limited (ASX:WWI) has achieved record monthly gold production in November by mining 14,725 tonnes and 3,760 tonnes of high and medium grade ore respectively at its Witwatersrand Basin Project in South Africa.
Australian producer West Wits Mining has announced it has acquired three in-production gold mining leases in the Pilbara with the intention of expanding its Tambina project, estimated to host a significant palaeo-placer gold deposit. The company already has interests in the lucrative Witswatersrand Basin in South Africa.
West Wits Mining Limited (ASX:WWI) is acquiring three Pilbara conglomerate gold mining leases (Tambina Project), along with a small-scale mining operation currently in place.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...